2,030 results on '"Moschini, Marco"'
Search Results
2. The effect of race/ethnicity on cancer-specific mortality after trimodal therapy
3. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer
4. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
5. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non–muscle-invasive Bladder Cancer
6. Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma
7. Long-term oncologic outcomes of robot-assisted radical cystectomy: update series from a high-volume robotic center beyond 10 years of follow-up
8. Topographic modification of the extracellular matrix precedes the onset of bladder cancer
9. Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy
10. Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel
11. Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes
12. The Impact of Venous Thromboembolism on Upper Tract Urothelial Carcinomas Undergoing Open or Minimally Invasive Radical Nephroureterectomy in the USA: Perioperative Outcomes and Health Care Costs from Insurance Claims Data
13. Online Crowdfunding for Urologic Cancer Care
14. Impact of smoking on urologic cancers: a snapshot of current evidence
15. Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis
16. Neoadjuvant Versus Adjuvant Chemotherapy in Non-Metastatic Locally-Advanced Stage Radical Cystectomy Candidates
17. Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non–muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics
18. Repeat Transurethral Resection for Non–muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era
19. Changes in renal function after nephroureterectomy for upper urinary tract carcinoma: analysis of a large multicenter cohort (Radical Nephroureterectomy Outcomes (RaNeO) Research Consortium)
20. Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer
21. Global burden, risk factors, and temporal trends of ureteral cancer: a comprehensive analysis of cancer registries
22. Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center
23. Robotic-assisted radical cystectomy with cutaneous ureterostomies: a contemporary multicenter analysis
24. Radical cystectomy in bladder cancer patients previously treated for prostate cancer: Insights from a large European multicentric series
25. Cost-analysis of robot-assisted radical cystectomy in Europe: A cross-country comparison
26. Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy
27. NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.
28. Re: Stamatio Katsimperis, Lazaros Tzelves, Zafer Tandogdu, et al. Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis. Eur Urol Focus 2023;9:920–9
29. PD02-05 THE IMPACT OF VENOUS THROMBOEMBOLISM ON MUSCLE INVASIVE BLADDER CANCER (MIBC) PATIENTS UNDERGOING OPEN OR MINIMALLY-INVASIVE RADICAL CYSTECTOMY IN THE UNITED STATES: PERIOPERATIVE OUTCOMES AND HEALTH-CARE COSTS FROM INSURANCE CLAIMS DATA
30. Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
31. PD02-06 COMPREHENSIVE GENOMIC PROFILING (CGP) OF CLINICAL T2-4N0M0 MUSCLE-INVASIVE BLADDER CANCER (MIBC) TREATED WITH NEOADJUVANT PEMBROLIZUMAB OR CISPLATIN-BASED CHEMOTHERAPY BEFORE RADICAL CYSTECTOMY (RC)
32. Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
33. PD41-10 UROLOGICAL FOLLOW-UP OF LYNCH SYNDROME: UTUC INCIDENCE AND MUTATIONAL PATTERNS IN A DEDICATED OUTPATIENT CLINIC
34. MP77-11 NOMOGRAM PREDICTING OPTIMAL CANDIDATES FOR BLADDER-SPARING STRATEGIES AFTER NEOADJUVANT IMMUNOTHERAPY
35. PD45-05 WHEN DOES SYSTEMATIC BIOPSY INFORMATION MATTER THE MOST? IDENTIFYING INDEPENDENT PREDICTORS OF DISEASE DOWNGRADING AT RADICAL PROSTATECTOMY IN HIGH GRADE PROSTATE CANCER BASED ON A LARGE MULTI-INSTITUTIONAL SERIES
36. MP53-04 NEOADJUVANT VERSUS ADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER: A DECISION ANALYSIS
37. PD30-06 PHOTODYNAMIC DIAGNOSIS (PDD) DIRECTED BIOPSIES VS WHITE LIGHT BLADDER MAPPING IN PATIENTS WITH POSITIVE CYTOLOGY AND NEGATIVE PREOPERATIVE WORKUP: AN INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY
38. MP71-15 CANCER CONTROL RATES IN ADEQUATE VERSUS INADEQUATE TREATMENT WITH ADJUVANT IMMUNOTHERAPY INSTILLATIONS WITH BCG
39. PD34-10 FIRST RESULTS OF NURE-COMBO: a PHASE 2 STUDY OF NEOADJUVANT NIVOLUMAB (NIVO) AND NAB-PACLITAXEL (ABX) FOLLOWED BY POSTSURGICAL ADJUVANT NIVO IN PATIENTS (PTS) WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC)
40. MP71-07 THE IMPACT OF CENTRALIZED UROPATHOLOGY REVIEW IN THE MANAGEMENT OF BLADDER CANCER PATIENTS AT THE TIME OF TRANSURETHRAL RESECTION OF THE BLADDER
41. MP16-11 LONG-TERM OUTCOMES OF PTA HIGH GRADE INTERMEDIATE AND HIGH RISK BLADDER CANCER PATIENTS
42. MP53-18 IMPACT OF NEOADJUVANT CHEMO-IMMUNOTHERAPY ON INTRA AND POST OPERATIVE OUTCOMES IN PATIENTS WITH BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY AND PELVIC LYMPH NODE DISSECTION: PROSPECTIVE SURGICAL ASSESSMENT FROM THE NURE-COMBO TRIAL
43. PD34-12 THE OPTIMAL NUMBER OF INDUCTION CHEMOTHERAPY CYCLES IN CLINICALLY LYMPH NODE-POSITIVE BLADDER CANCER
44. MP53-02 RISK OF NODE METASTASES IN MUSCLE INVASIVE BLADDER CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMO- OR IMMUNOTHERAPY AND RADICAL CYSTECTOMY WITH BILATERAL PELVIC LYMPH NODE DISSECTION
45. Temporal trends and cancer-specific mortality in non-metastatic muscle-invasive urothelial carcinoma of the urinary bladder treated with trimodal therapy
46. MP08-11 IMPACT OF PRE-SURGERY EGFR AND HER2 PLASMA LEVELS ON POST-SURGICAL OUTCOMES IN BLADDER CANCER PATIENTS RECEIVING RADICAL CYSTECTOMY
47. PD38-03 DETECTION OF LYMPH NODE INVOLVEMENT BEFORE RADICAL CYSTECTOMY: DIAGNOSTIC PERFORMANCE OF 18F-FDG PET/CT AND IMPLICATIONS IN THE THERAPEUTIC MANAGEMENT
48. MP38-20 RISK OF UPPER URINARY TRACT DISSEMINATION IN cT3 BLADDER CANCER PATIENTS TREATED WITH DOUBLE-J STENT VERSUS NEPHROSTOMY TUBE PRIOR TO RADICAL CYSTECTOMY
49. PD30-01 DEFINING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: A COMPARATIVE STUDY OF EAU AND IBCG CRITERIA
50. Carboplatin Induction Chemotherapy in Clinically Lymph Node–positive Bladder Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.